Spondyloarthritis & psoriatic arthritis
Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signalling pathways in spondyloarthritis
Authors' conclusion
CD29+IL-17RA+ T effector cells with enhanced Syk, NF-κB and JAK-STAT pathways were specifically increased in SpA and were correlated with disease activity, implicating a role of this newly identified T cell population in the pathogenesis.
Study context
- Population
- Patients with SpA (synovial fluid T cells from PsA; peripheral blood) and disease and healthy controls
- Participants
- 28 / 12 / 12 / 12 / 37
- Comparison
- SpA vs RA, IgG4-related disease (IgG4-RD), large vessel vasculitis (LVV) and healthy controls
- SpAn = 28
- RAn = 12
- IgG4-RDn = 12
- LVVn = 12
- Healthy controlsn = 37reference
- Outcome
- Peripheral blood CD29+IL-17RA+ T cells
Methodological detailstranscriptome analysis of public bulk RNA sequencing data, flow cytometry
- Transcriptome analysis of public bulk RNA sequencing data
- Flow cytometry
Main finding
As reported in the abstract
- T cells in inflamed PsA joints showed CD29 and IL-17RA expression
- CD29+IL-17RA+ T cells showed enriched CXCR3+CD45RA+ effector cells and activation of Syk, NF-κB and Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways
- Proportion of peripheral blood CD29+IL-17RA+ T cells significantly increased in SpA vs RA, IgG4-RD, LVV and healthy controls
- Proportion positively correlated with disease activity (ASDAS-CRP) in treatment-naïve active SpA
- Anti-IL-17 but not anti-TNF monoclonal antibodies reduced CD29+IL-17RA+ T cells
Original publication
Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signalling pathways in spondyloarthritis. Rheumatology (Oxford). Published 7 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →